CPT code 86709 designates a laboratory immunoassay that detects hepatitis A virus-specific immunoglobulin M (IgM) in patient serum, indicating recent or acute infection. This test is a key diagnostic tool in identifying active hepatitis A cases, guiding public health response and clinical management. Nationally, accurate billing and classification of this assay affect laboratory reporting, surveillance workflows, and payer coverage determinations.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for acute hepatitis A testing, typical sites of service for the assay, and the common billing considerations tied to laboratory immunoassays. The publication also summarizes benchmarks and coverage patterns where available, highlights relevant policy and coding clarifications, and outlines areas where clinical documentation supports appropriate use of the test.

This summary is intended for laboratory managers, billing professionals, and policy analysts seeking a national-level briefing on CPT code 86709 — what the code represents, why it matters for clinical diagnosis and public health, and the common payer landscape affecting reimbursement and utilization.